RefleXion and Merck: Is the Promise of Combining Drug and Device Therapy About to Be Realized?

article image

Creating anything like true drug-device convergence has proven elusive for medtech companies. But now oncology start-up RefleXion has entered into a novel collaboration with pharma giant Merck designed to prove that combining drugs and devices as independent agents can bring significant enhancements to each.

Typically, when medical devices and pharmaceuticals address the same clinical problem, they target very different populations: drugs, a front-line therapy seeking to treat all patients but almost always failing some; devices reserved for drug-resistant patients, sometimes of higher acuity.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: